Skip to Content

Glycopyrrolate / indacaterol Pregnancy and Breastfeeding Warnings

Glycopyrrolate / indacaterol is also known as: Utibron Neohaler

Glycopyrrolate / indacaterol Pregnancy Warnings

This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus. AU TGA pregnancy category: B3 US FDA pregnancy category: C Comments: Beta-agonists may potentially interfere with uterine contractility; women should contact their physician if they become pregnant while taking this drug.

Animal studies with glycopyrrolate or indacaterol do not indicate direct or indirect harmful effects with respect to reproductive toxicity at clinically relevant exposures. There were no effects on peri-natal and post-natal developments in rats at more than the maximum recommended human dose in adults. There are no controlled data with this drug or its individual components in human pregnancy. AU TGA pregnancy category B3: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncertain in humans. US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Glycopyrrolate / indacaterol Breastfeeding Warnings

Indacaterol: Indacaterol and its metabolites have been detected in the milk of lactating rats. Glycopyrrolate: Glycopyrrolate and its metabolites have been detected in the milk of lactating rats and reached up to 10-fold higher concentrations in the milk than in the blood of the dam. Reduced body weight gain was observed in pups of rats treated with indacaterol or glycopyrrolate, while impaired learning and decreased fertility were observed in pups of rats treated with indacaterol during pregnancy and lactation.

A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother. Excreted into human milk: Unknown (glycopyrrolate-indacaterol) Excreted into animal milk: Yes (glycopyrrolate-indacaterol) Comments: The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Utibron Neohaler (glycopyrrolate-indacaterol (glycopyrronium-indacaterol))." Novartis Pharmaceuticals, East Hanover, NJ.
  2. Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."
  3. Cerner Multum, Inc. "Australian Product Information." O 0
  4. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

References for breastfeeding information

  1. "Product Information. Utibron Neohaler (glycopyrrolate-indacaterol (glycopyrronium-indacaterol))." Novartis Pharmaceuticals, East Hanover, NJ.
  2. Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  4. Cerner Multum, Inc. "Australian Product Information." O 0

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide